appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Julie Zhang

BeOne Medicines, a global drug company that originated as a research and development (R&D) firm in Beijing, promoted Wang Lai to the newly created role of president, marking a leadership expansion as the company advances its late-stage pipeline and globalisation efforts.
The 48-year-old has served as the company’s global head of R&D since April 2021. Effective January, Wang would take the helm of an expanded portfolio, retaining his R&D responsibilities while also overseeing business development and the management of business alliance relationships, according to a filing with the Hong Kong stock exchange on Friday.
The appointment was approved by the board of directors on December 17.
Before becoming global R&D head in 2021, Wang held various research leadership positions in BeOne. Before that, he had helmed research operations as director at Joyant Pharmaceuticals, a Texas-based biotech company, from 2008 to 2011.

Wang, who holds US citizenship, earned a bachelor of science degree from Fudan University in 1996 and a PhD from the University of Texas Health Science Centre, San Antonio, in 2001.
He will serve alongside Wu Xiaobin, 63, as president of the company. Wu, a German citizen, previously served as country manager of Pfizer China and regional president of Pfizer Essential Health for Greater China before joining BeOne.
Wu received total pre-tax compensation of about 13.09 million yuan (US$1.86 million) last year, while Wang took home 8.56 million yuan, according to the company’s annual report.
BeOne generated global revenue of about US$3.8 billion last year, up from US$1.4 billion in the previous year, driven by its flagship products Brukinsa and Tevimbra.
Brukinsa, a BTK inhibitor that sells across the US, Europe, China, the UK, Canada, Australia, Japan, Brazil and other markets, achieved global sales of 18.7 billion yuan in 2024, ranking second globally and first in China in its class. The drug helped propel the company to its first profitable half-year in early 2024.
Tevimbra, a PD-1 antibody treatment, has secured regulatory approvals across the EU’s 27 member states plus Iceland and Norway, as well as 16 other countries in North America, Europe and Asia-Pacific.
As of February this year, BeOne held five patents for its medicines and late-stage clinical drug candidates.
Founded as BeiGene in 2010 by American entrepreneur John Oyler and Chinese-American scientist Wang Xiaodong, the company went public on the Nasdaq in 2016 and completed a secondary listing in Hong Kong two years later, followed by a Shanghai listing in 2021.
The company was rebranded as BeOne Medicines in November amid escalating US-China geopolitical tensions, having relocated its headquarters from the Cayman Islands to Switzerland in May.
As of December 2024, the company employed over 11,000 people globally.


As Chinese consumption of gold jewellery slumps 34%, sellers look to markets abroad: WGC

In a first, top European design prize awarded to €20 uniform for China’s delivery drivers

China cracks down on big firms delaying payments to cash-strapped SMEs

Veteran investor Fang Fenglei on why the China ‘investibility’ debate is no debate at all

China’s private sector

BeOne Medicines names R&D chief Wang Lai as president to lead global expansion

BeOne’s manufacturing facility in Guangzhou. Photo: Handout

BeOne Medicines promoted Wang Lai to the newly created role of president. Photo: Handout

China’s pharmaceutical sector moves into the big leagues as a global innovation powerhouse

China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP

An increasing number of early-stage biotech companies in China were engaging in large and wide-ranging clinical trial programmes. Photo: Xinhua

China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock

Leqembi, which costs a mainland Chinese patient about US$28,400 a year, may see its out-of-pocket price cut by half. Photo: Getty Images

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock

Shanghai Scizeng Medical Technology is a unit of Changchun High-Tech Industry. Photo: Handout

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

The collaboration is “another significant milestone in Fosun Pharma’s strategy of innovation and internationalisation”, according to the company. Photo: Reuters 

Pfizer has agreed to pay up to US$2.1 billion to Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug. Photo: Reuters

Business

China Business

Companies

News

China

Science

China Future Tech

Biomedicine

Tech

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra


BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.


BeOne Medicines names R&D chief Wang Lai as president to lead global expansion

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra